Related Experiment Video

Updated: Mar 1, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Investigating critical genes and gene interaction networks that mediate cyclophosphamide sensitivity in chronic

Xiao He1, Yuying Deng1, Wei Yue1

  • 1Blood Transfusion Department, The First People's Hospital of Yancheng City, Yancheng, Jiangsu 224006, P.R. China.

Molecular Medicine Reports
|June 1, 2017
PubMed

Insights

Drug resistance in chronic myelogenous leukemia (CML) is a major challenge. This study identifies key genes like STAT5A and S100A4 involved in cyclophosphamide resistance, offering new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Drug resistance significantly hinders effective treatment of chronic myelogenous leukemia (CML).
  • The precise mechanisms driving cyclophosphamide resistance in CML remain largely undefined.
  • Identifying these mechanisms is crucial for overcoming treatment failure and disease progression.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying cyclophosphamide resistance in chronic myelogenous leukemia (CML).
  • To identify differentially expressed genes (DEGs) and key pathways involved in CML drug resistance.
  • To validate the role of specific genes in mediating cyclophosphamide sensitivity.

Main Methods:

  • Microarray analysis of cyclophosphamide-sensitive and -resistant CML cell lines to identify DEGs.
  • Gene Ontology and KEGG pathway enrichment analysis to classify DEGs.
  • Construction of an interaction network to identify hub genes.
  • Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to confirm gene expression.
  • Gene knockdown experiments to assess functional involvement in drug resistance.

Main Results:

  • 258 DEGs were identified, with 139 upregulated and 119 downregulated between sensitive and resistant CML cells.
  • Enrichment analysis revealed 487 biological processes and 17 KEGG pathways associated with resistance.
  • Signal transducer and activator of transcription 5A (STAT5A), FYN, and spleen tyrosine kinase emerged as critical hub genes.
  • Knockdown of STAT5A and S100 calcium binding protein A4 (S100A4) restored sensitivity to cyclophosphamide in K-562 cells.

Conclusions:

  • STAT5A and S100A4 play significant roles in mediating cyclophosphamide resistance in CML.
  • The study identified novel genes and pathways contributing to CML drug resistance.
  • These findings provide a foundation for developing strategies to overcome cyclophosphamide resistance in CML patients.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.5K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65